Daily pill cuts body weight by up to 13% after 3 months in ... - NBC News
WEBSep 10, 2024 · A daily weight loss pill from Novo Nordisk was shown to lower body weight by up to 13% after three months in a Phase 1 clinical trial, according to findings presented Tuesday at the European...
Weight loss: Amycretin pill may be more effective than …
WEBSep 12, 2024 · Amycretin, a new weight loss drug developed by Novo Nordisk, has shown promising early results and is potentially more effective than the company’s established treatments, Ozempic and Wegovy.
'Remarkable' Weight Loss With Novel Oral Combo in Phase 1
WEB6 days ago · Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.
- Fast Company Novo Nordisk's weight-loss pill Amycretin beats …
WEBSep 11, 2024 · Amycretin’s phase 1 trials show study participants lost 13.1% of their body weight after only 3 months. That’s over twice the amount of weight loss on Wegovy, which shows about 6% weight loss ...
Novo Nordisk experimental obesity pill has mild-to-moderate side ...
WEBSep 10, 2024 · Patients who took 50 mg of amycretin at the end of the 12-week trial reduced body weight by 10.4% on average, while those taking the maximum dose of 2x50 mg lost 13.1% of their starting weight ...
Novo Nordisk weight loss pill may be more effective than …
WEBSep 10, 2024 · In a small Phase 1 trial, a 50-mg dose of the daily pill called amycretin, which activates receptors of both the amylin and GLP-1 hormones, led to 10.4% weight loss at about three months after...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
WEBSep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo’s latest obesity pill spurs major weight loss in small trial
WEBMar 7, 2024 · An experimental pill developed by Novo Nordisk helped obese people lose 13% of their body weight after three months of treatment in a small clinical trial, the company said Thursday, in a result one analyst described as among the best of any weight loss drug tested so far.
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
WEB2 days ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.
Experimental weight loss pill seems to be more potent than …
WEBMar 7, 2024 · Taking the oral pill amycretin resulted in people losing 13 per cent of their body weight over three months, more than twice that seen with Ozempic, but larger and longer studies are needed
Skip to content